Paper Details

  1. Home
  2. Paper Details

Focus on zavegepant: the first intranasal third-generation gepant.

Author: BagettaGiacinto, CorasanitiMaria Tiziana, ScuteriDamiana, TarsitanoAssunta, ToninPaolo

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This study provides an overview of the novel, third-generation intranasal zavegepant, a CGRP receptor antagonist for the treatment of migraine. It discusses its development and future perspectives, highlighting the potential benefits of intranasal administration and the need for real-world, long-term postmarketing data.
Paper Details　
Original Abstract of the Article :
Migraine is the leading cause of years lived with disability in people under 50 and its burden is increased by calcitonin gene-related peptide (CGRP)-driven chronicity. Newly approved small molecules that antagonize the CGRP receptor, gepants, have advanced from the hepatotoxic first-generation telc...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.2217/pmt-2022-0054

データ提供：米国国立医学図書館（NLM）

Zavegepant: A New Dawn for Migraine Treatment

Migraine, a debilitating condition that affects millions, can feel like a relentless desert storm, bringing pain and disruption to life. This research introduces a new weapon in the fight against migraine: zavegepant, a novel, third-generation gepant.

A Third-Generation Advance

Gepants, a class of drugs that target the CGRP receptor, have undergone significant development. Zavegepant, administered intranasally, represents a significant advancement over previous generations.

Hope for Migraine Sufferers

This research highlights the potential of zavegepant to provide relief from migraine pain, offering a promising new option for those struggling with this challenging condition. While the research is still ongoing, it holds great promise for the future of migraine treatment.

Dr.Camel's Conclusion

This research points to a brighter future for migraine sufferers, with zavegepant offering a new and potentially effective treatment option. The development of this third-generation gepant demonstrates the relentless pursuit of solutions to alleviate pain and improve the quality of life for those affected by migraine.

Date :
  1. Date Completed 2022-10-28
  2. Date Revised 2022-10-28
Further Info :

Pubmed ID

36189708

DOI: Digital Object Identifier

10.2217/pmt-2022-0054

Related Literature

Article Analysis
・Effects of atogepant
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.